Hepatitis B Virus Reactivation in COVID-19

Completed

• Conditions: COVID-19 Pneumonia; Hypoxemia; Hepatitis B

• Registration Number: NCT07154212
• Lead Sponsor: University Medical Centre Ljubljana

Brief Summary

The aim of this observational cohort study was to evaluate adherence to hepatitis B virus (HBV) screening guidelines in a country characterized by low HBV prevalence and assess the potential reactivation and progression of HBV infection in anti-HBV core antigen antibodies (anti-HBc) positive patients receiving corticosteroids for coronavirus disease 2019 (COVID-19).

Detailed Description

Not available

Study Timeline

• Study Start: 2020-11-01
• Primary Completion: 2022-04-08
• Study Completion: 2022-04-08
• Status Verified: 2025-09
• Study First Submitted: 2025-09-02
• Study First Submitted QC: 2025-09-02
• Last Update Submitted: 2025-09-02
• Study First Posted: 2025-09-04
• Last Update Posted: 2025-09-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1793

Inclusion Criteria

• hospitalized adult patients with a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ribonucleic acid (RNA) polymerase chain reaction (PCR) test
• supplemental oxygen
• treated with corticosteroids for COVID-19 pneumonia

Exclusion Criteria

• age under 18 years
• hospitalized for medical conditions unrelated to COVID-19
• received corticosteroid therapy for non-COVID-19 reasons

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HBV reactivation	at least 3 months post treatment with corticosteroids	number (%) of patients with HBV reactivation
number (%) of patients with HBV reactivation	one year

Trial Locations

Locations (1)

University Medical Centre Ljubljana; 🇸🇮 Ljubljana, Slovenia